Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 2/20 | 0.31 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27596746 | 0.83 | TSHR (0.35) | ATMCYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL12253207 | 0.81 | ADH1C (0.43) | ATMTSHRCA1CA2ADH1C | |
| SCHEMBL27862543 | 0.79 | TSHR (0.37) | ATMCYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL1566319 | 0.78 | ADH1C (0.40) | TSHRCA1CA2HCAR2ADH1C | |
| SCHEMBL3139541 | 0.78 | ADH1C (0.36) | TSHRHPGDCA1CA2HCAR2 | |
| SCHEMBL9767729 | 0.77 | ADH1C (0.39) | TSHRHPGDCA1CA2HCAR2 | |
| SCHEMBL8422500 | 0.76 | ATM (0.38) | ATMCYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL1274837 | 0.75 | — | — | |
| SCHEMBL10773593 | 0.75 | TSHR (0.40) | TSHRHPGDCA1CA2ADH1C | |
| SCHEMBL13761201 | 0.75 | AKR1B1 (0.41) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1784416-A | 9-ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-06-07 | — | — | CN | claimed |
| EP-1590358-A1 | 9-KETOSPINOSYN DERIVATIVES | Bayer CropScience Aktiengesellschaft (DE) | 2005-11-02 | — | — | EP | claimed |
| WO-2004065402-A1 | 9-KETOSPINOSYN DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-08-05 | — | — | WO | claimed |
| CN-1918128-B | fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD | 2011-01-26 | — | — | CN | disclosed |
| CN-1922183-B | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD | 2010-05-26 | — | — | CN | disclosed |
| CN-100404544-C | 9-ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2008-07-23 | — | — | CN | disclosed |
| US-7312200-B2 | 9-ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2007-12-25 | — | — | US | disclosed |
| CN-1960977-A | Quinazoline derivative | BANYU PHARMA CO LTD (JP) | 2007-05-09 | — | — | CN | disclosed |
| CN-1922183-A | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| CN-1918128-A | Fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
| US-20060128642-A1 | 9-Ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| CN-1784416-A | 9-ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1590358-A1 | 9-KETOSPINOSYN DERIVATIVES | Bayer CropScience Aktiengesellschaft (DE) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065402-A1 | 9-KETOSPINOSYN DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-08-05 | — | — | WO | disclosed |
| CN-1077110-C | 13-substituted milbemycin 5-oxime derivatives their preparation and their use against insects and other pests | SANKYO CO (JP) | 2002-01-02 | — | — | CN | disclosed |
| CN-1072652-C | Substd. benzoylaminothiazole derivatives and drugs containing same | ZERIA PHARM CO LTD (JP) | 2001-10-10 | — | — | CN | disclosed |
| CN-1234028-A | Substd. benzoylaminothiazole derivatives and drugs containing same | ZERIA PHARM CO LTD (JP) | 1999-11-03 | — | — | CN | disclosed |
| CN-1216986-A | Isoxazole derivatives | SANKYO CO (JP) | 1999-05-19 | — | — | CN | disclosed |
| CN-1153177-A | 13-substituted milbemycin 5-oxime derivatives their preparation and their use against insects and other pests | SANKYO CO (JP) | 1997-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128642-A1 | 9-Ketospinosyn derivatives | SNX9, NANS, BROX | ATM 4636/4885CYP3A4 2733/4885TSHR 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.